The beginning of the year has been full of exciting changes. To comply with government guidelines for Covid-19 measures and requirements for workspaces as well as to increase experimental capacity MediSieve expanded their Lab Space in February 2021

The expansion enabled MediSieve to have full control over safety and equipment to meet the company's R&D needs. Previously MediSieve shared a laboratory with other companies in the White City Innovation Hub, which inevitably made R&D slower. By moving to a new fully equipped laboratory MediSieve  hopes to not only keep the significant progress in research going but advance it futher.

MediSieve's CTO Cristina Blanco-Andujar commented that:

"The expansion of the lab space has improved our workflow hugely as we now have dedicated areas for different activities so everything can be very controlled. In addition, this new space represents our development over the last year and makes our progression feel really tangible. The team is very excited about the future."

Expanding the lab space is a first step towards further growth and product development of the company.

About MediSieve

MediSieve is a biotech company, developing “Magnetic Blood Filtration”, a combination of a device and a therapeutic platform of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From sepsis to malaria to leukaemia and viral infections, such as COVID-19, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk

Sort by: Newest First Oldest First Most Popular Most unliked